CANSINOBIO (06185) Obtains PIC/S GMP Certificate for MCV4 and PCV13i

Bulletin Express03-05

CanSino Biologics Inc. (CANSINOBIO, 06185) announced that the manufacturing site for its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) and 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i) has passed the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Good Manufacturing Practice (GMP) compliance inspection conducted by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). The company has recently been granted a GMP certificate by the NPRA.

According to the announcement dated March 5, 2026, this certification indicates that the manufacturing and quality management systems meet PIC/S GMP standards. This achievement will facilitate progress in the registration and marketing of MCV4 and PCV13i in Malaysia and other PIC/S member countries. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166699407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166699407","market":"us","top_or_hot":-1,"title":"CANSINOBIO (06185) Obtains PIC/S GMP Certificate for MCV4 and PCV13i","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO, 06185) announced that the manufacturing site for its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) and 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i) has passed the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Good Manufacturing Practice (GMP) compliance inspection conducted by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). The company has recently been granted a GMP certificate by the NPRA.</p>\n<p>According to the announcement dated March 5, 2026, this certification indicates that the manufacturing and quality management systems meet PIC/S GMP standards. This achievement will facilitate progress in the registration and marketing of MCV4 and PCV13i in Malaysia and other PIC/S member countries. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO (06185) Obtains PIC/S GMP Certificate for MCV4 and PCV13i</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO (06185) Obtains PIC/S GMP Certificate for MCV4 and PCV13i\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 17:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO, 06185) announced that the manufacturing site for its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) and 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i) has passed the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Good Manufacturing Practice (GMP) compliance inspection conducted by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). The company has recently been granted a GMP certificate by the NPRA.</p>\n<p>According to the announcement dated March 5, 2026, this certification indicates that the manufacturing and quality management systems meet PIC/S GMP standards. This achievement will facilitate progress in the registration and marketing of MCV4 and PCV13i in Malaysia and other PIC/S member countries. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1166699407","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166699407","pubTimestamp":1772702870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO, 06185) announced that the manufacturing site for its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) and 13-valent Pneumococcal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物(06185)获得MCV4和PCV13i的PIC/S GMP证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO, 06185) announced that the manufacturing site for its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) and 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i) has passed the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Good Manufacturing Practice (GMP) compliance inspection conducted by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). The company has recently been granted a GMP certificate by the NPRA.\nAccording to the announcement dated March 5, 2026, this certification indicates that the manufacturing and quality management systems meet PIC/S GMP standards. This achievement will facilitate progress in the registration and marketing of MCV4 and PCV13i in Malaysia and other PIC/S member countries. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166699407","isCrawlerRequest":true}